KYNB Company Profile and Key Details

Kyntra Bio, Inc. generated EPS of $40.44 over the past year. Five-year average earnings growth is 11.75%. Wall Street analysts project EPS growth of -6.88% annually over the next five years. Kyntra Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended November 10, 2025, missed forecasts by -59.85%. The prior quarter beat by 50.22%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in March 17, 2025.

Short-term trend indicators are bullishly aligned (SMA20 -7.46%, SMA50 -14.42%, SMA200 -18.61%). The stock’s 14-day RSI is 40.14 (neutral), while the ATR of 0.63 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -44.08% below its high and over 49.9% above its low. Average 10-day trading volume of 46.13 thousand shares is slightly above the 3-month average of 32.60 thousand, indicating heightened recent market interest.

Kyntra Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.26. This means the shares are trading below this model’s fair value.

Kyntra Bio, Inc. (NASDAQ:KYNB) closed at $7.27 USD, losing -$0.01 (-0.14%) from the previous close of $7.28. The stock is currently mid-range between its 52-week high and low $4.85 and $16.25. With a market capitalization of about $29.41 million, Kyntra Bio, Inc. is classified as a micro-cap and shows market-like volatility (beta ~0.83). Key stats such as the average daily volume over the past year has been around 32.53 thousand shares, in line with its 52-week average. Headquartered in San Francisco, CA, Kyntra Bio, Inc. operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Thane Wettig, the company employs approximately 225 people and listed since November 14, 2014. Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics.

Our AI price prediction model suggests that Kyntra Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.24%, with price expected at $7.36 by March 11, 2026, within a range of $7.02 to $7.66 3-Month Outlook: Projected fall of -13.76%, reaching $6.27 by May 26, 2026, with a range of $6.22 to $6.32. 1-Year Outlook: Projected loss of -99.72%, with price at $0.02 by February 25, 2027, within a range of $0.00 to $0.09.

Kyntra Bio, Inc. (NASDAQ:KYNB) shares are flat -2.62% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Kyntra Bio, Inc. trading at a premium to the broader market with a P/E of 0.14. Our AI forecast model points to short-term strength (1.24% over two weeks), a medium-term fall (-13.76% over three months), and a longer-term loss (-99.72% over one year), with expected trading ranges indicating moderate volatility.

Kyntra Bio, Inc. trades at a P/E ratio of 0.14, slightly below the S&P 500 average, with a price-to-sales ratio of -0.25 and a price-to-book ratio of -1.71 indicating negative book value, which may reflect financial stress. The P/FCF stands at -1.71, also above market averages.